Suspension Mass Cytometry and Imaging Mass Cytometry
The MCC works closely with investigators to design research goal–driven, metal-labeled antibody panels and to rigorously validate antibodies using established positive and negative control cells and tissue sections for suspension mass cytometry (CyTOF) and imaging mass cytometry (IMC). The MCC has developed and validated multiple antibody panels for imaging mass cytometry applications and is expanding these capabilities to support suspension mass cytometry–based studies. In parallel, the core has established a state-of-the-art pipeline for quantitative analysis of high-dimensional, single-cell data.
Core Services Include:
- design and procurement of application-specific antibody panels,
- in-house metal conjugation of antibodies,
- panel validation and sample staining for CyTOF and IMC studies, and
- data acquisition and downstream data analysis using the Bodenmiller Lab pipeline.
The core also offers validated marker panels spanning key biological domains, including epithelial-to-mesenchymal transition, metabolic pathways, tumor microenvironment characterization, cancer type–specific protein markers, proliferation, and cancer stem cell biology.
Technology Seminar: Overview of the new Mass Cytometry Core at FNLCR
Spatial Proteomics with Imaging Mass Cytometry
Milind M. Pore, Ph.D. (FNLCR), Scientist II, Mass Cytometry Core (MCC), Cancer Research Technology Program.
Resolving the Osteosarcoma Microenvironment Using Spatial Omics
Troy A. McEachron, Ph.D., Principal Investigator, Pediatric Oncology Branch.
Application of IMC to Inform Lung Immunity in Fatal COVID-19 Cases
Daniel S. Chertow, MD, MPH, Principal Investigator and Head, Emerging Pathogens Section
Stephen M. Hewitt, MD, PhD, Director, Clinical Trials Correlative Core, and Director, CLIA Molecular Diagnostics Laboratory, FNLCR
Visit the OSTR Technology Videos page to view this recording.